Skip to content

Shulman Fasciitis Prevalence Study in Alsace

Shulman Fasciitis Prevalence Study in Alsace

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02829112
Acronym
SHULMAN
Enrollment
30
Registered
2016-07-12
Start date
2016-07-31
Completion date
2017-07-31
Last updated
2017-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shulman Fasciitis

Keywords

Shulman, fasciitis, Shulman fasciitis, eosinophilic fasciitis, inflammatory disease, prevalence

Brief summary

Shulman fasciitis or eosinophilic fasciitis (EF) is a rare inflammatory disease, usually benign but disabling, described by Shulman in 1974. The diagnosis is suggested by the clinic, confirmed by MRI and confirmed by histology, there really no published diagnostic criteria validated for this rare disease. The low number of cases reported in the literature reflects the difficulty of studying the epidemiology of this disease, to establish and evaluate therapeutic strategies and to assess prognosis. Work on this subject are few. To our knowledge, no study has previously used to estimate the incidence and prevalence of this disease. Therefore, the investigators want to determine the prevalence of FEs in Alsace in 2016 by a study capture-recapture using several independent sources of identification of cases in order to have recent epidemiological data and learn more about this disease.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged over 18 years * Patients suffering from fasciitis Shulmande and living in Alsace at 1 January 2016

Exclusion criteria

* refusal to participate in the study

Design outcomes

Primary

MeasureTime frame
Estimation of the prevalence of Shulman fasciitis in Alsace, the calculation will be carried out using the numerator of all the cases identified and in the denominator the general population (Alsatian population of both sexes)all living patients in Alsace from 1 January 2016 to december 2016

Countries

France

Contacts

Primary ContactJean SIBILIA, MD, PhD
jean.sibilia@chru-strasbourg.fr33 (0)3 88 12 79 54
Backup ContactLionel Spielmann, MD
lionel.spielmann@chru-strasbourg.fr33 (0)3 88 12 79 54

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026